Roughly 25,000 to 32,000 Americans are living with amyotrophic lateral sclerosis (ALS) at any given time, though the exact number depends on which counting method you trust. The most recent federal estimate puts the prevalence rate at about 10 per 100,000 people, which is higher than figures cited even a few years ago. That upward shift is not necessarily because more people are getting ALS; it reflects better methods for finding cases the registry used to miss.
What the National ALS Registry Actually Counts
The U.S. National ALS Registry, run by the Agency for Toxic Substances and Disease Registry (a branch of the CDC), is the primary system for tracking how many Americans have ALS. It pulls data from Medicare, Medicaid, the Veterans Health Administration, and a web portal where patients can self-identify. Even so, the registry has always known it undercounts. In a completeness evaluation, the registry captured only about 54 to 56 percent of ALS cases between 2011 and 2014, with people under 65 and people of color particularly underrepresented.1PubMed. Evaluation of the Completeness of ALS Case Ascertainment in the US National ALS Registry: Application of the Capture-Recapture Method
To compensate, researchers use a statistical technique called capture-recapture, which estimates how many people the registry is missing by comparing overlapping data sources. Using this approach on 2017 data, the registry identified a conservative lower bound of about 17,800 cases (a prevalence of 5.5 per 100,000) but estimated a mean case count closer to 24,800, with an upper-bound estimate near 31,800 cases, or about 9.9 per 100,000.2PubMed Central. Prevalence of amyotrophic lateral sclerosis in the United States using established and novel methodologies, 2017 The most recent dashboard figure of about 10.1 per 100,000 reflects continued refinement of those methods.3Centers for Disease Control and Prevention. National ALS Registry Dashboard
The gap between the raw count and the corrected estimate matters because it shapes everything from research funding to health-system planning. If you see a headline claiming “about 16,000 Americans have ALS,” that figure likely comes from the uncorrected registry tally; if you see one saying “over 30,000,” it comes from the high end of capture-recapture models. Neither is wrong exactly, but the corrected estimate is the one epidemiologists consider more realistic.
How Many New Cases Appear Each Year
Prevalence tells you how many people are living with the disease at a snapshot in time. Incidence tells you how many new diagnoses show up each year. The registry recorded roughly 5,000 to 6,000 new cases annually between 2014 and 2016, which translates to an age-adjusted incidence of about 1.5 to 1.7 per 100,000 people per year.4PubMed. Incidence of amyotrophic lateral sclerosis in the United States, 2014-2016 Because those raw numbers suffer from the same undercounting issues, the true annual incidence is probably somewhat higher.
ALS is often called a rare disease, and by any formal definition it is. But “rare” can be misleading. With roughly 5,000 or more new diagnoses each year and a median survival of two to five years after symptom onset, the living population of people with ALS turns over quickly. That rapid turnover is why the prevalence stays relatively low even though the disease is not vanishingly uncommon. It also means that a surprisingly large number of Americans will receive an ALS diagnosis over the course of a decade.
Who Is Most Likely to Be Diagnosed
ALS is not evenly distributed across the population. Three demographic patterns show up consistently in the data: age, sex, and race.
The highest prevalence rates fall in the 60-to-79 age range.5Nature Communications. Projected increase in amyotrophic lateral sclerosis from 2015 to 2040 ALS can appear in younger adults, but it is far less common before age 40. The disease’s concentration in older age groups is one reason the total number of cases is projected to grow as the U.S. population ages.
Men are diagnosed more often than women, with a male-to-female ratio that typically lands between 1.5 and 1.7 to one.6Morbidity and Mortality Weekly Report. Prevalence of Amyotrophic Lateral Sclerosis — United States, 2012–2013 That gap narrows with age, though. One population-based study found that the male-to-female ratio dropped from above 2.5 in younger adults to below 1.5 after menopause, suggesting that hormonal factors may offer some protective effect earlier in life.7PubMed Central. The sex ratio in amyotrophic lateral sclerosis: A population based study
Racial differences are also well documented. ALS occurs less frequently among Black, Asian, and Hispanic Americans than among white Americans.8PubMed Central. Racial and ethnic differences among amyotrophic lateral sclerosis cases in the United States An obvious question is whether this reflects real biological differences or just unequal access to neurologists who can make the diagnosis. Research using mortality data and adjusting for socioeconomic status, insurance type, and birthplace concluded that the higher rate among whites likely reflects genuinely higher risk rather than ascertainment bias.9PubMed Central. Race/ethnicity, socioeconomic status, and ALS mortality in the United States That said, the registry’s own completeness studies show that non-white patients are underrepresented in the data, so the gap may be somewhat smaller than current numbers suggest.1PubMed. Evaluation of the Completeness of ALS Case Ascertainment in the US National ALS Registry: Application of the Capture-Recapture Method
Geographic Patterns Across the Country
ALS cases are spread across all 50 states, but not uniformly. California, Florida, and Texas have the largest raw numbers of cases, which makes sense given their population sizes. When adjusted for population, though, the Midwest has the highest rate at about 5.7 per 100,000, followed by the Northeast at 5.2, the South at 4.7, and the West at 4.3.10PubMed Central. A spatial analysis of amyotrophic lateral sclerosis (ALS) cases in the United States and their proximity to multidisciplinary ALS clinics, 2013 State-level data from 2011 through 2018 showed an average prevalence of 4.4 per 100,000, with Vermont at the high end (7.8) and Hawaii at the low end (2.6). New England and Midwest states consistently sat above the national average.11PubMed. Prevalence of ALS in all 50 states in the United States, data from the National ALS Registry, 2011-2018
Whether these geographic differences point to environmental causes or just demographic variation is a long-running question. Researchers have looked for spatial clusters of unusually high incidence in places like New Jersey and Northern New England. A study in New Jersey found no statistically significant clusters, though ALS incidence tended to be higher in wealthier areas and lower in lower-income areas, which may reflect diagnostic access more than true risk differences.12PubMed Central. Geographic Variation of Amyotrophic Lateral Sclerosis Incidence in New Jersey, 2009–2011 A study covering Northern New England, by contrast, did identify 11 clusters of significantly elevated incidence grouped in four distinct regions.13PubMed. Spatial analysis of amyotrophic lateral sclerosis in Northern New England, USA, 1997-2009 The mixed findings are typical of ALS cluster research: some areas look suspicious, but definitive environmental links remain elusive.
The Elevated Risk Among Veterans
Military veterans have consistently shown higher rates of ALS than the general population, and in 2008 Congress recognized this by making ALS a presumptive service-connected disease for VA benefits purposes. The elevated risk has been reported across different service eras and branches.14Epidemiologic Reviews. Military Service, Deployments, and Exposures in Relation to Amyotrophic Lateral Sclerosis Etiology and Survival What researchers have not pinned down is exactly why. Is it combat exposure? Chemical agents encountered during deployment? Intense physical training? A matched case-control study found that while military service itself is an established risk factor, it remains unclear whether the association is linked specifically to combat.15PubMed Central. Military Service Roles and ALS Among Veterans: A Matched Case-Control Study
This matters for the prevalence picture because veterans make up a substantial share of the ALS population, and they are captured relatively well by the registry thanks to VA health records. Any change in the size or age distribution of the veteran population will ripple into overall ALS numbers.
Familial Versus Sporadic ALS
About 5 to 10 percent of ALS cases run in families, a category known as familial ALS. The remaining 90 to 95 percent appear without any known family history and are classified as sporadic.16PubMed Central. Estimated Familial Amyotrophic Lateral Sclerosis Proportion: A Literature Review and Meta-Analysis That distinction is important for counting purposes because familial cases tend to get diagnosed somewhat earlier and are more likely to be connected to specialized ALS clinics. Sporadic cases, especially in people without a family context that raises suspicion, can take longer to diagnose.
Diagnostic delay is a persistent problem. Incorrect initial diagnoses, failure to consider a neurological cause for symptoms, and delayed referral to a neurologist are major factors that can stretch the time from first symptoms to diagnosis to a year or more.17PubMed. Diagnostic delay in amyotrophic lateral sclerosis: what scope for improvement? During that window, a person with ALS exists but has not yet been counted. Shortening diagnostic delays would simultaneously improve patient care and make the registry’s snapshot more accurate.
How the U.S. Compares Globally
Among countries with reliable surveillance data, the United States sits near the top of the prevalence ladder. A systematic review of global data found point prevalence ranging from 1.57 per 100,000 in Iran to 11.80 per 100,000 in the United States.18PubMed Central. Global Prevalence and Incidence of Amyotrophic Lateral Sclerosis: A Systematic Review Part of this reflects genuine population-level risk differences, but a lot of it is about measurement. Countries with older populations, universal healthcare, and well-funded registries will always report higher numbers than countries where many ALS patients never see a neurologist.
Globally, the number of ALS cases is expected to climb substantially. One projection estimated an increase from about 223,000 cases worldwide in 2015 to roughly 377,000 by 2040, a jump of about 69 percent, driven largely by population aging.5Nature Communications. Projected increase in amyotrophic lateral sclerosis from 2015 to 2040 The U.S. will be part of that trend. As the baby-boom generation moves deeper into the peak-risk age range, prevalence numbers are likely to continue edging upward even if the underlying rate of new cases per 100,000 stays flat.
Environmental Exposures Under Investigation
For the roughly 90 percent of ALS cases that are sporadic, researchers have spent decades looking for environmental triggers. The evidence is strongest, if still not definitive, for a handful of exposures. A case-control study using National ALS Registry data found that occupational exposure to lead (including soldering, welding with metal dust, and use of lead paint or leaded gasoline) was significantly associated with ALS risk. That same study flagged certain organochlorine pesticides: blood levels of heptachlor, alpha-endosulfan, and oxychlordane all correlated with higher ALS risk.19PubMed. Case-control study of environmental toxins and risk of amyotrophic lateral sclerosis involving the national ALS registry
A separate geospatial analysis of pesticides applied to crops found statistically significant positive associations between ALS risk and several widely used chemicals, including the herbicides 2,4-D and glyphosate and the insecticides carbaryl and chlorpyrifos.20PubMed Central. Pesticides applied to crops and amyotrophic lateral sclerosis risk in the U.S. These are associations, not confirmed causal links, and the effect sizes are modest. But they are consistent with a broader pattern in ALS research suggesting that cumulative exposure to certain neurotoxicants nudges risk upward, particularly in people who may already carry genetic susceptibility.
The Financial Burden Per Person and Nationally
ALS is one of the more expensive diseases to manage, and costs accelerate sharply as the disease progresses. An analysis of U.S. insurance claims found that annualized healthcare costs averaged about $31,400 in the early stage, $51,500 in the middle stage, and roughly $121,900 in the late stage, driven primarily by more frequent and costlier hospital admissions.21PubMed Central. Health care resource utilization and costs across stages of amyotrophic lateral sclerosis in the United States Those figures capture only direct medical spending and do not account for home modifications, specialized equipment like power wheelchairs and communication devices, or lost income for both patients and family caregivers.
At the national level, one literature review estimated total annual costs at roughly $1 billion, calculated against a prevalence estimate of about 16,000 cases. The range across different studies spanned from about $212 million to $1.4 billion per year, depending on which costs were included and which prevalence figure was used.22PubMed. Epidemiology and economic burden of amyotrophic lateral sclerosis in the United States: a literature review If the true number of Americans with ALS is closer to 25,000 or 30,000, the real national cost is correspondingly higher than the published estimates that relied on smaller prevalence counts. The economic picture is another reason the undercounting question is not just academic. The number of people you think have a disease shapes how much money gets allocated to treating it.
Why Death Certificates Do Not Tell the Whole Story
You might assume that mortality records would provide a clean backstop for counting ALS cases, since the disease is almost always fatal. But death certification for ALS is neither fully sensitive nor fully specific, meaning it both misses some ALS deaths and occasionally labels non-ALS deaths as ALS.23PubMed. Validating population-based registers for ALS: how accurate is death certification? A patient whose death certificate lists respiratory failure or pneumonia as the cause may have died of ALS without the disease being recorded. Conversely, some deaths labeled as motor neuron disease turn out on closer review to be other conditions. This means that even mortality-based estimates carry their own margin of error, and statistical exercises that combine registry data with death certificate data can inadvertently overcount or undercount depending on the specific errors involved.
For patients and families trying to navigate the system, these counting challenges have tangible consequences. Research funding, drug development timelines, insurance coverage decisions, and state-level support programs all hinge partly on how prevalent a disease is believed to be. The steady improvement in U.S. surveillance methods over the past decade has been genuinely helpful, but the honest summary is that we still do not know the exact number of Americans living with ALS. What we know is the range, and that range has been narrowing.